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Context. Essential for adequate management of breakthrough cancer pain is a combination of accurate (re-)assessment
and a personalized treatment plan. The Breakthrough Pain Assessment Tool (BAT) has been proven to be a brief,
multidimensional, reliable, and valid questionnaire for the assessment of breakthrough cancer pain.
Objectives. The aim of this study was to examine the validity and reliability of the Dutch Language version of the BAT
(BAT-DL) in patients with cancer.
Methods. The BAT was forward-backward translated into the Dutch language. Thereafter, the psychometric properties of
the BAT-DL were tested, that is factor structure, reliability (internal consistency and test-retest reliability), validity (content
validity and construct validity), and the responsiveness to change.
Results. The BAT-DL confirmed the two-factor structure in 170 patients with cancer: pain severity/impact factor and pain
duration/medication efficacy factor. The Cronbach’s alpha coefficient was 0.72, and the intraclass correlation for the test-
retest reliability was 0.81. The BAT-DL showed to be able to differentiate between different group of patients and correlated
significantly with the Brief Pain Inventory. In addition, the BAT-DL was capable to detect clinically important changes over
time.
Conclusion. The BAT-DL is a valid and reliable questionnaire to assess breakthrough pain in Dutch patients with cancer
and is a relevant questionnaire for daily practice. J Pain Symptom Manage 2020;-:-e-.  2019 American Academy of Hospice
and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
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This article describes a prospective study that
tested the psychometric factors of the Dutch lan-
guage version of the Breakthrough Pain Assessment
Tool (BAT-DL) in 170 patients with cancer-related
pain. The results indicate that the BAT-DL is a valid
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Published by Elsevier Inc. All rights reserved.seems to be a relevant questionnaire for daily
practice.
Introduction
Pain is one of the most common symptoms in pa-
tients with cancer. Depending on the cancer type,
stage of the disease, and setting, 33%e64% of theAccepted for publication: December 2, 2019.
0885-3924/$ - see front matter
https://doi.org/10.1016/j.jpainsymman.2019.12.009
2 Vol. - No. - - 2020Oldenmenger et al.patients with cancer experience pain.1 Moreover, half
of the patients with cancer-related pain experience
breakthrough cancer pain (BTcP).2 Breakthrough
pain has been defined as a transient exacerbation of
pain that occurs either spontaneously or in relation
to a specific predictable or unpredictable trigger,
despite relatively stable and adequately controlled
background pain.3 Characteristics of BTcP are the
rapid onset of the pain, short duration, frequent
occurrence, and moderate-to-severe intensity.4e6
BTcP interferes with daily activities. Patients with
BTcP report loss of control, changes in lifestyle, and
diminished quality of life.4e7
Because the intensity, impact, and consequences of
BTcP varies per patient, a thorough (re-)assessment of
patients’ pain and a personalized treatment plan is
required to successfully manage the pain.8,9 Patients’
pain assessment exists of a thorough examination
and a detailed history, inclusive of detailed informa-
tion about the different aspects of the exacerbations
of the pain.8,9
The Breakthrough Pain Assessment Tool (BAT) has
been developed for the assessment and monitoring of
BTcP in daily practice, based on published guidelines,
and a Delphi process with pain experts in codesign
with 10 patients with BTcP.4,10 Thereafter, the psycho-
metric factors of the questionnaire were tested in 100
patients with cancer: it was proven to be a multidimen-
sional, reliable, and valid questionnaire for the assess-
ment of BTcP.10 The aim of this study was to examine
the validity and reliability of the Dutch Language
version of the BAT (BAT-DL).Methods
In this study, the BAT was first translated into the
Dutch language, after which the psychometric proper-
ties of the BAT-DL were tested.
Translation
We translated the BAT into the Dutch language ac-
cording the European Organisation for Research and
Treatment of Cancer guidelines.11 The forward trans-
lation was performed by two Dutch physician-nurse
couples, experts in palliative care. The project man-
ager merged the translated questionnaires into one
questionnaire. Subsequently, four native-English
health care professionals translated the question-
naire back into English, after which the four versions
were synthesized. The final backward-translated ques-
tionnaire was confirmed by the authors of the orig-
inal BAT. The BAT-DL was tested by 15 patients with
BTcP. Every patient self-completed the questionnaire,
and afterward, the project manager interviewed these
patients to determine if the questions were difficult
to answer, difficult to understand, confusing,shocking or offensive, and finally what other sugges-
tions they would have to reformulate the question.
As a result, we reformulated the Dutch language of
two questions after agreement with all eight transla-
tors. The final version of the BAT-DL was approved
by the pain consultation team of the Erasmus Univer-
sity Medical Center (MC), the translators and
involved patients.
Psychometric Properties
The psychometric properties of the BAT-DL were
tested in a prospective multicenter observational study
conducted at the Erasmus MC, Netherlands Cancer
Institute, Martini Hospital, University Medical Center
Utrecht, Rijnstate Hospital, Spaarne Hospital, and
Hospice Kuria. The ethic committee of each of the
participating centers approved the study. The study
was conducted in accordance with the Declaration of
Helsinki and the local governance procedures. All pa-
tients provided written informed consent.
Patients. The psychometric properties of the BAT-DL
were assessed in 170 patients with cancer. Each insti-
tute had a study coordinator who was responsible for
the inclusion. All patients were recruited from the
inpatient and outpatient populations. The inclusion
criteria were histologically confirmed diagnosis of can-
cer; pain because of cancer or its treatment; regular
scheduled analgesia taken in the previous week; break-
through pain according to a pain specialist;3,12 use of
at least one dose of rescue medication for an episode
of BTcP in the previous week; cognitive status suffi-
cient for accurate completion of the study; and age
older than 18 years, Dutch speaking, and able to pro-
vide written informed consent. Exclusion criteria were
patients whose performance status13 was too poor to
allow them to complete the study as judged by a
pain specialist.
Measurements. Patients completed a questionnaire
containing the BAT-DL and Brief Pain Inventory
(BPI) at baseline and after a week. In addition, pa-
tients were asked to provide demographic informa-
tion and complete questions about the adequacy of
BTcP and the need for changes in their analgesics.
At the same time, pain specialists assessed all patients
at baseline and were asked to provide clinical infor-
mation, for example, performance status, using the
Eastern Cooperative Oncology Group (ECOG) per-
formance status,13 and to complete questions about
the adequacy of breakthrough pain control, the
need for changes in the patients’ analgesics, and to
report the current analgesic regimen. During the
assessment after a week, both patients and clinicians
were asked to comment on any change in the break-




Number of Patients (N ¼ 170), n
(%)









Head and neck 18 (11)
Sarcoma 9 (5)
Multiple myeloma 6 (4)
Melanoma 5 (3)
Others 5 (3)
Disease stage, n (%)
Locally advanced 34 (20)
Metastatic 130 (77)
Unknown 6 (4)
Subject type, n (%)
Outpatient 40 (24)
Inpatient 130 (76)
Anticancer treatment, n (%)
None 55 (32)
Chemotherapy 55 (32)
Hormonal therapy 14 (8)
Radiotherapy 42 (25)
Other 33 (20)
Pain etiology, n (%)
Cancer-related 132 (78)
Cancer treatment-related 13 (8)
Mixed 24 (14)
Unknown 2 (1)





Pain intensity, mean (SD)
Current pain 3.4 (2.1)
Average pain 4.8 (1.9)
Worst pain 8.1 (1.5)
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responsiveness to change of the BAT-DL. In addition,
an extra assessment took place, 24 hours after base-
line, when patients were asked to complete the
BAT-DL to assess the test-retest reliability of the
questionnaire.10,14
The BAT-DL contains 14 questions evaluating cur-
rent pain management: nine questions related to
pain and five questions related to the pain treatment.
In six questions, 0e10 Numerical Rating Scales are
used; in three questions, categorical scales are used;
in four questions, free text; and in one question, a
body shape outline to mark the site of the pain is
used.10
The BPI measures pain intensity and daily interfer-
ence on a 0e10 Numerical Rating Scale. Pain intensity
is measured as current pain, worst pain, average pain,
and least pain. Interference by pain in daily life (daily
interference) is assessed by seven items: general activ-
ity, mood, walking ability, normal work, sleep, relations
with other people, and enjoyment of life. A mean
interference score is computed by taking the average
of the seven items. In addition, there is one question
on the benefit of the treatment rated as the percent-
age of pain relief (0% ¼ no relief and
100% ¼ complete relief).15,16
Data Analysis. The data of this study were analyzed
using IBM SPSS, Version 25 (IBM Corporation, Ar-
monk, NY). Descriptive statistics (percentages, means,
and SD) were used to present the study sample’s de-
mographics and disease-related characteristics.
Different aspects of validity and reliability were
analyzed (Appendix Table 1). Structural validity was
determined by confirmatory factor analysis. We hy-
pothesized a two-factor structure for the BAT-DL,
based on the structure of the original BAT.10
Construct validity was measured by a known-group
analysis; the between-group differences were calcu-
lated using an independent t-test. Convergent validity
was determined by correlating BAT item scores and
related measurements, using a Pearson correlation
analysis for continuous variables and the Spearman
rank-order correlation analysis for ranked or ordered
variables. Responsiveness to change was calculated to
determine whether the BATcan detect clinically signif-
icant changes in breakthrough pain. For this analysis,
we used both patients’ and clinicians’ assessment of
the BTcP after one week. Internal consistency reli-
ability was estimated by Cronbach’s alpha coefficients.
Test-retest reliability was analyzed by calculation of the
intraclass correlation coefficients between the baseline
data and after 24 hours to measure whether the BAT
was stable under similar conditions (Appendix
Table 1).Results
Between August 2015 and August 2018, we included
170 patients with BTcP. The median age was 61 years
(range 30e89); 56% were males; the most common
cancer sites were gastrointestinal (22%), urological
(20%), and breast (19%); and 77% of the patients
had metastatic disease (Table 1). Twelve patients
(7%) did not complete the assessment after 24 hours,
and 17 patients (10%) did not complete the assess-
ment after a week. The main reasons for this were pa-
tients who felt too unwell to complete the
questionnaire (n ¼ 10), problems getting in contact
with the patient (n ¼ 5), or the reason was unknown
(n ¼ 2).
According to the pain specialist, 49% of the patients
had incident BTcP, 10% spontaneous BTcP, and 41%
had a combination. The most prevalent frequency of
BTcP was greater than four times a day (45%), and
Table 2




How often do you get
breakthrough pain?
0.474
How long does a typical episode of
breakthrough pain last?
0.592
How severe is your worst
breakthrough pain?
0.598
How severe is a typical
breakthrough pain?
0.662
How much does the breakthrough
pain distress you?
0.854
How much does the breakthrough
pain stop you from living a
normal life?
0.797




How long does the painkiller take
to have meaningful effect?
0.794




BAT ¼ Breakthrough Pain Assessment Tool.
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five minutes (19%) to >60 minutes (15%)
(Appendix Table 2). Most patients reported that their
pain significantly interfered with their daily life
(Appendix Table 3). Most patients had cancer-
related pain, used long-acting opioids for their back-
ground pain (median morphine equivalent daily
dose 120 mg [interquartile range 60,240 mg]), and
immediate-release opioids (80%) and/or rapid-onset
opioids (20%) for their BTcP (Appendix Table 4;
Table 1).Reliability
The questions of the BAT-DL loaded onto two fac-
tors, a pain severity and impact factor and a pain duration
and medication efficacy factor (Table 2). The Cronbach’s
alpha coefficient for the BAT-DL was 0.72. The values
for the separate factors were 0.76 (pain severity and
impact factor) and 0.27 (pain duration and medica-
tion efficacy factor). To determine the test-retest reli-
ability, we calculated the intraclass correlation
coefficient for the BAT-DL (0.81; 95% CI 0.74e0.87),
pain severity and impact factor (0.88; 95% CI
0.83e0.92), and pain duration and medication effi-
cacy factor (0.60; 95% CI 0.43e0.73).Validity
In the group with patient-determined adequately
controlled BTcP, the mean scores for all BAT-DL ques-
tions were statistically significantly lower compared
with the group with patient-determined inadequately
controlled BTcP, except for two questions (How longdoes the painkiller take to have a meaningful effect and
How much do the side effects for the breakthrough painkiller
bother you). This was confirmed with the clinicians’
global impression of BTcP, except for the question
How long does a typical episode of BTcP last?, which was
not significant (Table 3).
Patients with an ECOG performance status of 3e4
scored statistically significantly higher on BAT-DL
questions about pain severity, distress, and interfer-
ence compared with patients with an ECOG status of
0e2.
The correlations between the BAT-DL and the BPI
are presented in Table 4. There was a strong correla-
tion between the item How severe is your worst BTcP?
and the BPI worst pain item (r ¼ 0.65). The BAT-
DL item How severe is a typical BTcP? has a strong cor-
relation with the BPI items’ worst pain (r ¼ 0.55) and
average pain (r ¼ 0.54). In addition, the BAT-DL
item How much does the BTcP stop you from living a
normal life? was strongly correlated with the BPI
item general activity (r ¼ 0.59), work (r ¼ 0.57),
and the BPI total item (r ¼ 0.55). The BAT-DL
item How effective is the painkiller for your BTcP was
strongly correlated to the BPI item pain relief
(r ¼ 0.65; Table 4).
The BAT-DL was able to detect clinically significant
changes in BTcP (Table 5). When patients assessed
their BTcP after a week as better, six of the nine
BAT-DL items were also statistically significantly lower
compared with the baseline measurements. When the
clinician assessed patients’ pain as better after a week,
patients scored five of the nine BAT-DL items statisti-
cally significantly lower compared with the baseline
measurements (Table 5).Discussion
In this study, we translated the BAT into the Dutch
language. The BAT-DL showed to be a valid and reli-
able instrument for the assessment and evaluation of
breakthrough pain in Dutch patients with cancer,
and it is a relevant questionnaire for daily practice.
The factor analysis showed that the BAT-DL loaded
onto two factors, pain severity and impact factor and
pain duration and medication efficacy factor, similar
to the other validation studies in the U.K. and South
Korea.10,14 However, the last question, How much do
the side effects from the breakthrough painkiller bother you?,
loaded in the Korean version onto the second factor.
Our present study confirmed the factors and factor
loading of the original study.10
An important feature of the BAT-DL is that this
questionnaire is able to distinguish various groups of
patients, such as between groups with adequately vs.
inadequately controlled BTcP. As expected, patients
with inadequately controlled BTcP had significantly
Table 3
Comparison of BAT by Global Impression of Breakthrough Pain Control
BAT Items












(N ¼ 43) P
How often do you get breakthrough pain? 5.2 (2.0) 6.6 (1.5) 0.000 5.4 (1.9) 6.4 (1.8) 0.006
How long does a typical episode of breakthrough
pain last?
5.5 (2.4) 6.4 (2.4) 0.041 5.8 (2.4) 5.9 (2.5) 0.816
How severe is your worst breakthrough pain? 6.9 (2.2) 7.7 (1.5) 0.009 6.8 (2.1) 8.1 (1.4) 0.000
How severe is a typical breakthrough pain? 4.99 (2.1) 5.98 (1.6) 0.002 4.9 (2.0) 6.4 (1.3) 0.000
How much does the breakthrough pain distress
you?
5.95 (2.5) 7.4 (1.8) 0.000 5.97 (2.5) 7.5 (1.6) 0.000
How much does the breakthrough pain stop you
from living a normal life?
6.2 (2.9) 7.9 (2.0) 0.000 6.2 (2.9) 8.2 (1.5) 0.000
How effective is the painkiller for your
breakthrough pain (reversed)?
2.6 (1.7) 4.4 (2.1) 0.000 3.0 (2.0) 3.9 (1.9) 0.011
How long does the painkiller take to have
meaningful effect?
6.5 (1.8) 6.6 (2.1) 0.604 6.4 (1.9) 6.6 (1.9) 0.709
How much do the side effects from your
breakthrough painkiller bother you?
2.9 (2.8) 3.7 (3.1) 0.127 3.0 (2.9) 3.5 (3.0) 0.308
BAT ¼ Breakthrough Pain Assessment Tool; BTcP ¼ breakthrough cancer pain.
Significance of bold values is as follows: P-value # 0.5.
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adequately controlled. In contrast to the original
study, our study also showed a statistically significant
improvement of pain intensity and distress in patients
in whom BTcP became adequately controlled accord-
ing to the clinicians.10 However, the differences be-
tween these groups at two other questions (about
time to a meaningful effect and side effects) were
not significant in our study in contrast to the U.K.
study.10 The Korean study did not describe such an
analysis.14 Another comparison was based on the per-
formance status. As expected, patients with a bad per-
formance also scored worse at the BAT, especially on
items about pain intensity, pain interference, and
distress, as in the original study.10
The BAT-DL correlated well with the BPI (conver-
gent validity). The BAT-DL pain severity items, inter-
ference items, as well as the distress items were
moderately good correlated with the BPI total inter-
ference item, the same as in the original study.10
The Korean study did not report on the BPI total
interference item.14 In addition, the items about the
worst and typical BTcP episode correlated well with
all BPI pain intensity items in the present study, com-
parable to the Korean study.14 However, in the U.K.
study, these two items showed no correlation with
BPI least pain intensity and current pain intensity.10
Moreover, the BAT-DL items about distress and
disruption of normal life correlated well to most BPI
questions, comparable to the earlier studies.10,14
This confirmed that there is an easier way to ask for
interference of pain. Based on the known-group ana-
lyses and the convergent validity, we conclude that the
BAT-DL demonstrated acceptable levels of construct
validity.Another important factor for daily practice is the
ability to demonstrate clinically relevant changes
over time. The BAT-DL confirmed the responsiveness
to change of the BAT10 to detect clinically significant
changes in BTcP. When the BTcP was scored as better
after a week (Table 5), especially the pain severity and
interference items scored statistically significantly
lower at the questionnaire one week later. The only
item that did not show a difference was about the
side effects; however, patients scored the influence
of side effects already as mild at baseline.
Finally, the BAT-DL demonstrated acceptable levels
of reliability: test-retest reliability (>0.8) and internal
consistency (>0.7), both above the recommended cut-
off,17 comparable to the two earlier studies.10,14 There-
fore, the BAT-DL seems to be a reliable questionnaire
for breakthrough pain assessment in patients with
cancer.
As all studies, this study has some limitations. An
advantage is that this is a multicenter study; however,
the consequence is a possible variation in clinical ex-
periences in BTcP. In every hospital, a pain specialist
included the patients, which might have caused varia-
tion in patients’ pain management. However, this is
also a reflection of daily practice. Some of the hospi-
tals had problems to include patients as most of the
patients had uncontrolled background pain, and
therefore, these patients did not adhere to the defini-
tion of BTcP we used in this study.3 The included pa-
tients had BTcP as assessed by a pain specialist,3
although some patients independently scored their
pain intensity >4 on the research questionnaire. The
definition of BTcP does not use any description
related to pain intensity. In this study, the clinical ex-
amination was used as the gold standard.3 An
Table 4
Convergent Validity Between BAT and BPI
BAT Items















How often do you get
breakthrough pain?
0.217 0.190 0.364 0.321 L0.355 0.477 0.307 0.206 0.389 0.122 0.252 0.236 0.367
How long does a typical
episode of BTcP last?
0.202 0.308 0.237 0.326 0.158 0.031 0.172 0.17 0.057 0.182 0.064 0.168 0.165
How severe is your worst
breakthrough pain?
0.646 0.358 0.468 0.361 0.239 0.340 0.262 0.227 0.317 0.203 0.209 0.214 0.318
How severe is a typical
breakthrough pain?
0.551 0.334 0.540 0.468 0.209 0.400 0.423 0.176 0.285 0.329 0.428 0.293 0.410
How much does the BTcP
distress you?
0.447 0.287 0.375 0.323 0.277 0.466 0.324 0.188 0.391 0.277 0.354 0.300 0.436
How much does the BTcP
stop you
from living a normal life?
0.441 0.184 0.346 0.250 0.239 0.594 0.397 0.385 0.569 0.237 0.266 0.417 0.549
How effective is the
painkiller
for your BTcP?
0.05 0.159 0.211 0.276 0.652 0.288 0.157 0.153 0.228 0.084 0.027 0.066 0.200
How long does the
painkiller for
your BTcP take to have a
meaningful effect?
0.119 0.169 0.100 0.097 0.036 0.056 0.017 0.144 0.121 0.051 0.054 0.011 0.066




0.165 0.260 0.287 0.166 0.040 0.193 0.395 0.131 0.171 0.097 0.225 0.222 0.257
BAT ¼ Breakthrough Pain Assessment Tool; BPI ¼ Brief Pain Inventory; BTcP ¼ breakthrough cancer pain.
Correlation coefficient values >0.1 represent a small correlation, >0.3 medium, and >0.5 large.





















Responsiveness to Change Based on Assessment of BTcP Baseline Compared With One Week Later
BAT Items
Patient’s Assessment of BTcP Better (N ¼ 71)
Clinician’s Assessment of BTcP Better
(N ¼ 75)
Baseline After One Week
P
Baseline After One Week
PMean (SD) Mean (SD)
How often do you get
breakthrough pain?
7.8 (1.6) 5.5 (2.0) 0.000 6.8 (1.7) 5.5 (1.9) 0.000
How long does a typical episode of
breakthrough pain last?
5.8 (2.5) 5.4 (2.3) 0.167 5.6 (2.5) 5.6 (2.5) 0.925
How severe is your worst
breakthrough pain?
8.2 (1.4) 6.8 (2.3) 0.000 8.0 (1.6) 6.6 (2.1) 0.000
How severe is a typical
breakthrough pain?
6.2 (1.7) 4.7 (1.9) 0.000 6.0 (1.8) 4.8 (2.0) 0.000
How much does the breakthrough
pain distress you?
7.6 (2.1) 5.9 (2.7) 0.000 7.4 (2.2) 6.1 (2.6) 0.000
How much does the breakthrough
pain stop you from living a
normal life?
7.6 (2.2) 5.9 (2.7) 0.000 7.5 (2.2) 6.6 (2.8) 0.004
How effective is the painkiller for
your breakthrough pain
(reversed)?
3.5 (2.3) 2.6 (1.6) 0.005 3.3 (2.1) 3.1 (2.1) 0.696
How long does the painkiller take
to have meaningful effect?
6.8 (2.3) 6.5 (1.8) 0.313 6.4 (2.2) 6.4 (1.9) 1.0
How much do the side effects
from your breakthrough
painkiller bother you?
3.4 (3.1) 2.8 (2.7) 0.228 3.7 (2.9) 2.9 (2.8) 0.233
BTcP ¼ breakthrough cancer pain.
Significance of bold values is as follows: P-value # 0.5.
Vol. - No. - - 2020 7Breakthrough Pain Assessment Tooladvantage of the present study was the number of
included patients (n ¼ 170), which ensured that there
were enough patients for the subgroup analyses.
In conclusion, this study confirmed that the BAT-DL
is a valid and reliable questionnaire to assess break-
through pain in patients with cancer.Disclosures and Acknowledgments
The authors acknowledge the assistance of the staff
at the research institutions: Erasmus University Medi-
cal Center, Netherlands Cancer Institute, Martini Hos-
pital, University Medical Center Utrecht, Rijnstate
Hospital, Spaarne Hospital, VU University Medical
Center, and Hospice Kuria, The Netherlands. In addi-
tion, they thank Dr. Andrew Davies for his contribu-
tion during the translation of the questionnaire.
This work was financially supported by a grant from
the Innovation Fund of the Dutch Health Insurers,
The Netherlands, without any influence on study
design, analysis, interpretation, or presentation.
Ethical approval: The study protocol was approved
by the Institutional Review Board of the Erasmus MC
(MEC-2013-056).
The authors declare no conflicts of interest.References
1. van den Beuken-van Everdingen MH, Hochstenbach LM,
Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update onprevalence of pain in patients with cancer: systematic re-
view and meta-analysis. J Pain Symptom Manage 2016;51:
1070e1090.e9.
2. Deandrea S, Corli O, Consonni D, Villani W, Greco MT,
Apolone G. Prevalence of breakthrough cancer pain: a sys-
tematic review and a pooled analysis of published literature.
J Pain Symptom Manage 2014;47:57e76.
3. Davies AN, Dickman A, Reid C, Stevens AM,
Zeppetella G. The management of cancer-related break-
through pain: recommendations of a Task Group of the Sci-
ence Committee of the Association for Palliative Medicine of
Great Britain and Ireland. Eur J Pain 2009;13:331e338.
4. Webber K, Davies AN, Cowie MR. Breakthrough pain: a
qualitative study involving patients with advanced cancer.
Support Care Cancer 2011;19:2041e2046.
5. Davies A, Zeppetella G, Andersen S, et al. Multi-centre
European study of breakthrough cancer pain: pain charac-
teristics and patient perceptions of current and potential
management strategies. Eur J Pain 2011;15:756e763.
6. Bedard G, Hawley P, Zhang L, et al. A survey of Canadian
cancer patients’ perspectives on the characteristics and treat-
ment of breakthrough pain. Support Care Cancer 2013;21:
2557e2563.
7. Hjermstad MJ, Kaasa S, Caraceni A, et al. Characteristics
of breakthrough cancer pain and its influence on quality of
life in an international cohort of patients with cancer. BMJ
Support Palliat Care 2016;6:344e352.
8. Vissers KCP, Van den Beuken-van Everdingen MHJ, Dij-
stra D, et al. Dutch guideline: Diagnostics and treatment
of pain in patients with cancer. 2016, Nederlandse Verenig-
ing voor Anesthesiologie, Utrecht, The Netherlands.
9. Davies AN, Elsner F, Filbet MJ, et al. Breakthrough can-
cer pain (BTcP) management: a review of international and
8 Vol. - No. - - 2020Oldenmenger et al.national guidelines. BMJ Support Palliat Care 2018;8:
241e249.
10. Webber K, Davies AN, Zeppetella G, Cowie MR. Develop-
ment and validation of the breakthrough pain assessment
tool (BAT) in cancer patients. J Pain Symptom Manage
2014;48:619e631.
11. Dewolf L, Koller M, Velikova G, et al. EORTC quality of
life group, translation procedure, 3rd ed. Brussels: EORTC,
2009.
12. Webber K. Development of the Breakthrough Pain
Assessment Tool (BAT) in cancer patients. Int J Palliat
Nurs 2014;20:424.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and
response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol 1982;5:649e655.14. Shin J, Cho SJ, Lee J, Choi YS. Validation of the
Korean version of the Breakthrough Pain Assessment
Tool in cancer patients. J Pain Symptom Manage 2017;
54:361e367.
15. Enting RH, Oldenmenger WH, Van Gool AR, van der
Rijt CC, Sillevis Smitt PA. The effects of analgesic prescrip-
tion and patient adherence on pain in a Dutch outpatient
cancer population. J Pain Symptom Manage 2007;34:
523e531.
16. Cleeland CS, Ryan KM. Pain assessment: global use of
the Brief Pain Inventory. Ann Acad Med Singapore 1994;
23:129e138.
17. Cronbach L, Warrington W. Coefficient alpha and inter-
nal structure of tests. Psychometrika 1951;16:297e334.
Vol. - No. - - 2020 8.e1Breakthrough Pain Assessment ToolAppendixAppendix Table 2
Breakthrough Pain Assessment Tool
BAT Items
Baseline (N ¼ 170) After One Day (N ¼ 153) After One Week (N ¼ 153)
Mean (SD)
How often do you get breakthrough pain? 6.5 (1.7) 6.1 (1.9) 5.7 (1.9)
How long does a typical episode of breakthrough
pain last?
5.6 (2.6) 5.9 (2.6) 5.8 (2.4)
How severe is your worst breakthrough pain? 8.2 (1.5) 7.5 (1.7) 7.2 (2.0)
How severe is a typical breakthrough pain? 6.2 (1.7) 5.5 (1.7) 5.3 (2.0)
How much does the breakthrough pain distress
you?
7.2 (2.1) 6.7 (2.2) 6.5 (2.4)
How much does the breakthrough pain stop you
from living a normal life?
7.3 (2.3) 7.0 (2.4) 6.8 (2.7)
How effective is the painkiller for your
breakthrough pain? (reversed)
3.3 (2.1) 3.3 (2.0) 3.2 (2.0)
How long does the painkiller take to have
meaningful effect?
6.7 (2.2) 6.7 (2.1) 6.5 (1.9)
How much do the side effects from your
breakthrough painkiller bother you?
3.4 (3.0) 3.4 (2.8) 3.1 (2.9)
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The purpose of this analysis was to ensure that the items correlate with the remainder of the
questionnaire
 Cronbach’s alpha coefficients were calculated for the six questions with a 0e10 Numeric
Rating Scale
 Cronbach’s alpha coefficient >0.7 indicate good internal consistency17
Test-retest reliability The purpose was to ensure that the underlying construct is stable, and that similar results are
reached over two distinct periods in unchanged conditions
 In patients who scored their BTcP as stable after 24 hours, the intraclass correlation
coefficient was calculated for the BAT-DL and the two factors
Validity
Structural validity
The purpose of this analysis is to determine whether the instrument is an adequate reflection of
the dimensionality of the construct to be measured
Hypothesis: The BAT-DL will confirm the two-factor structure of the original BAT
 Confirmatory factor analysis
Content validity During the translation of the BAT, the project group, a group of clinical experts, assessed the
BAT-DL and gave their opinion on its relevance, appropriateness, and to what extent the BAT is a
sufficient assessment tool for breakthrough pain
Construct validity
Known group analysis/hypothesis testing
The purpose of this analysis was to determine the ability of the BAT to differentiate between
different group of patients
Hypothesis: BAT scores should be significantly higher in patients defined as having inadequately
controlled BTcP
 Patient-determined adequately controlled BTcP vs. inadequately controlled BTcP
 Clinician-determined adequately controlled BTcP vs. inadequately controlled BTcP (Table 3)
Hypothesis: BAT scores should be significantly higher in patients with a lower performance status
 Patients with ECOG performance status 3e4 vs. ECOG performance status 0e2
Construct validity
Convergent validity
The purpose of these analysis was to determine correlations between the BAT item scores and
related measures:
 BPI item scores and total interference score (Table 4)
Responsiveness to change The purpose of this analysis was to determine whether the BAT can detect clinically important
changes over time that are related to BTcP
 BAT item scores at baseline vs. BAT item scores after a week in patients who assessed their
BTcP as better after a week
 BAT item scores at baseline vs. BAT item scores after a week in patients whose clinician
assessed their BTcP as better after a week (Table 5)





Baseline (N ¼ 170) After One Week (N ¼ 150)
Mean (SD)
Worst pain intensity 8.1 (1.5) 7.1 (2.1)
Least pain intensity 2.4 (1.7) 2.4 (1.7)
Average pain intensity 4.8 (1.9) 4.4 (1.9)
Current pain intensity 3.4 (2.1) 3.4 (2.2)
Pain relief (%) 69.9 (20.4) 66.2 (22.1)
Pain interference: general activity 6.4 (2.7) 5.7 (2.7)
Pain interference: mood 4.4 (2.8) 4.4 (2.7)
Pain interference: walking ability 5.6 (3.4) 5.3 (3.1)
Pain interference: normal work 7.1 (3.0) 6.6 (3.0)
Pain interference: sleep 4.2 (3.1) 3.5 (2.8)
Pain interference: relations with other people 3.5 (3.0) 3.4 (2.8)
Pain interference: enjoyment of life 4.6 (2.9) 4.8 (2.9)





(N ¼ 170), n (%)
After One Week
(N ¼ 152), n (%)
MEDD (mg/day);
median (IQR)
120 (60, 240) 120 (60, 270)
Analgesics, Step 1
Paracetamol 157 (92) 138 (91)





Morphine 32 (19) 25 (16)
Fentanyl 72 (42) 63 (41)
Oxycodone 50 (29) 43 (28)
Hydromorphone 15 (9) 19 (13)
Buprenorphine 2 (1) 1 (1)
Methadone 4 (2) 4 (3)
Adjuvant analgesics
Antidepressants 18 (11) 18 (12)
Anticonvulsants 42 (25) 41 (27)
Steroids 7 (4) 5 (3)
Rescue analgesics
Morphine (IR) 48 (28) 36 (24)
Oxycodone (IR) 71 (42) 65 (43)
Hydromorphone (IR) 15 (9) 19 (13)
Fentanyl (IV) 1 1 (1)
Buprenorphine (IR) 2 (1) 1 (1)
Intranasal
fentanyl spray
4 (2) 2 (1)
Sublingual fentanyl 30 (18) 31 (20)
MEDD ¼ morphine equivalent daily dose; IQR ¼ interquartile range;
NSAID ¼ nonsteroidal anti-inflammatory drug; IR ¼ immediate release;
IV ¼ intravenous.
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